Sustained improvement of clinical outcome with risperidone long-acting injectable in psychotic patients previously treated with olanzapine.

The efficacy and tolerability of risperidone long-acting injectable were investigated in patients with schizophrenia or other psychotic disorders who had previously been symptomatically stable on olanzapine treatment. Patients received risperidone long-acting injectable, 25 mg, by intramuscular injection every 2 weeks; the dose could be increased to 37.5 or 50 mg if necessary.

[Respiratory effects of risperidone? A prospective study].

Risperidone is an atypical neuroleptic which has been incriminated as a cause of respiratory symptoms. The purpose of this prospective study was to assess over a three-month period the respiratory status of patients free of allergic or respiratory disease treated with risperidone. Thirty-nine patients were enrolled.

[Use and value of the therapeutic neuroleptic-bromocriptine combination in schizophrenia].

Use and interest of therapeutic association bromocriptine-neuroleptic in schizophrenia. Twelve schizophrenic patients were treated by bromocriptine (7.5 mg.

[Arguments for early treatment of refractory schizophrenia].

The authors, taking up their experience and the literature, attempt to view the precociousness of alternative, classical neuroleptic treatments in schizophrenia, from notion of treatment-resistant schizophrenia, precocious refractory and intolerance. Until now, clozapine was administrated to patients lasting resistant and in mainly cases hospitalized since many years. As such as quality of life and economy of health, it would be desirable to quickly think of alternatives neuroleptic's therapeutic protocols and clozapine in the treatment-resistant schizophrenias or those presenting an intolerance.